nodes	percent_of_prediction	percent_of_DWPC	metapath
Tapentadol—UGT2B7—Epirubicin—ovarian cancer	0.333	0.673	CbGbCtD
Tapentadol—CYP2D6—Vinorelbine—ovarian cancer	0.0755	0.152	CbGbCtD
Tapentadol—CYP2C9—Paclitaxel—ovarian cancer	0.058	0.117	CbGbCtD
Tapentadol—CYP2D6—Doxorubicin—ovarian cancer	0.0286	0.0577	CbGbCtD
Tapentadol—Cardiac disorder—Docetaxel—ovarian cancer	0.000848	0.00181	CcSEcCtD
Tapentadol—Vomiting—Topotecan—ovarian cancer	0.000847	0.00181	CcSEcCtD
Tapentadol—Vertigo—Paclitaxel—ovarian cancer	0.000843	0.0018	CcSEcCtD
Tapentadol—Syncope—Paclitaxel—ovarian cancer	0.000842	0.0018	CcSEcCtD
Tapentadol—Lethargy—Doxorubicin—ovarian cancer	0.000842	0.0018	CcSEcCtD
Tapentadol—Rash—Topotecan—ovarian cancer	0.00084	0.00179	CcSEcCtD
Tapentadol—Hypersensitivity—Vinorelbine—ovarian cancer	0.000839	0.00179	CcSEcCtD
Tapentadol—Dermatitis—Topotecan—ovarian cancer	0.000839	0.00179	CcSEcCtD
Tapentadol—Ataxia—Epirubicin—ovarian cancer	0.000838	0.00179	CcSEcCtD
Tapentadol—Headache—Topotecan—ovarian cancer	0.000834	0.00178	CcSEcCtD
Tapentadol—Palpitations—Paclitaxel—ovarian cancer	0.00083	0.00177	CcSEcCtD
Tapentadol—Angiopathy—Docetaxel—ovarian cancer	0.000829	0.00177	CcSEcCtD
Tapentadol—Vomiting—Melphalan—ovarian cancer	0.000829	0.00177	CcSEcCtD
Tapentadol—Immune system disorder—Docetaxel—ovarian cancer	0.000826	0.00177	CcSEcCtD
Tapentadol—Loss of consciousness—Paclitaxel—ovarian cancer	0.000825	0.00176	CcSEcCtD
Tapentadol—Osteoarthritis—Doxorubicin—ovarian cancer	0.000825	0.00176	CcSEcCtD
Tapentadol—Mediastinal disorder—Docetaxel—ovarian cancer	0.000824	0.00176	CcSEcCtD
Tapentadol—Rash—Melphalan—ovarian cancer	0.000822	0.00176	CcSEcCtD
Tapentadol—Dermatitis—Melphalan—ovarian cancer	0.000821	0.00176	CcSEcCtD
Tapentadol—Chills—Docetaxel—ovarian cancer	0.00082	0.00175	CcSEcCtD
Tapentadol—Cough—Paclitaxel—ovarian cancer	0.000819	0.00175	CcSEcCtD
Tapentadol—Asthenia—Vinorelbine—ovarian cancer	0.000817	0.00175	CcSEcCtD
Tapentadol—Convulsion—Paclitaxel—ovarian cancer	0.000813	0.00174	CcSEcCtD
Tapentadol—Pruritus—Vinorelbine—ovarian cancer	0.000806	0.00172	CcSEcCtD
Tapentadol—Breast disorder—Epirubicin—ovarian cancer	0.000805	0.00172	CcSEcCtD
Tapentadol—Aspartate aminotransferase increased—Epirubicin—ovarian cancer	0.000803	0.00172	CcSEcCtD
Tapentadol—Mental disorder—Docetaxel—ovarian cancer	0.000801	0.00171	CcSEcCtD
Tapentadol—Arthralgia—Paclitaxel—ovarian cancer	0.000799	0.00171	CcSEcCtD
Tapentadol—Nasopharyngitis—Epirubicin—ovarian cancer	0.000797	0.0017	CcSEcCtD
Tapentadol—Anxiety—Paclitaxel—ovarian cancer	0.000797	0.0017	CcSEcCtD
Tapentadol—Malnutrition—Docetaxel—ovarian cancer	0.000796	0.0017	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000794	0.0017	CcSEcCtD
Tapentadol—Nausea—Topotecan—ovarian cancer	0.000791	0.00169	CcSEcCtD
Tapentadol—Alanine aminotransferase increased—Epirubicin—ovarian cancer	0.000786	0.00168	CcSEcCtD
Tapentadol—Dry mouth—Paclitaxel—ovarian cancer	0.000782	0.00167	CcSEcCtD
Tapentadol—Diarrhoea—Vinorelbine—ovarian cancer	0.000779	0.00167	CcSEcCtD
Tapentadol—Ataxia—Doxorubicin—ovarian cancer	0.000775	0.00166	CcSEcCtD
Tapentadol—Nausea—Melphalan—ovarian cancer	0.000774	0.00166	CcSEcCtD
Tapentadol—Confusional state—Paclitaxel—ovarian cancer	0.000773	0.00165	CcSEcCtD
Tapentadol—Anaphylactic shock—Paclitaxel—ovarian cancer	0.000766	0.00164	CcSEcCtD
Tapentadol—Oedema—Paclitaxel—ovarian cancer	0.000766	0.00164	CcSEcCtD
Tapentadol—Infection—Paclitaxel—ovarian cancer	0.000761	0.00163	CcSEcCtD
Tapentadol—Shock—Paclitaxel—ovarian cancer	0.000754	0.00161	CcSEcCtD
Tapentadol—Dizziness—Vinorelbine—ovarian cancer	0.000753	0.00161	CcSEcCtD
Tapentadol—Nervous system disorder—Paclitaxel—ovarian cancer	0.000751	0.00161	CcSEcCtD
Tapentadol—Tachycardia—Paclitaxel—ovarian cancer	0.000748	0.0016	CcSEcCtD
Tapentadol—Breast disorder—Doxorubicin—ovarian cancer	0.000745	0.00159	CcSEcCtD
Tapentadol—Skin disorder—Paclitaxel—ovarian cancer	0.000744	0.00159	CcSEcCtD
Tapentadol—Aspartate aminotransferase increased—Doxorubicin—ovarian cancer	0.000743	0.00159	CcSEcCtD
Tapentadol—Hyperhidrosis—Paclitaxel—ovarian cancer	0.000741	0.00158	CcSEcCtD
Tapentadol—Nasopharyngitis—Doxorubicin—ovarian cancer	0.000737	0.00158	CcSEcCtD
Tapentadol—Alanine aminotransferase increased—Doxorubicin—ovarian cancer	0.000727	0.00155	CcSEcCtD
Tapentadol—Vomiting—Vinorelbine—ovarian cancer	0.000724	0.00155	CcSEcCtD
Tapentadol—Rash—Vinorelbine—ovarian cancer	0.000718	0.00154	CcSEcCtD
Tapentadol—Dermatitis—Vinorelbine—ovarian cancer	0.000718	0.00153	CcSEcCtD
Tapentadol—Hypotension—Paclitaxel—ovarian cancer	0.000716	0.00153	CcSEcCtD
Tapentadol—Upper respiratory tract infection—Epirubicin—ovarian cancer	0.000716	0.00153	CcSEcCtD
Tapentadol—Headache—Vinorelbine—ovarian cancer	0.000714	0.00153	CcSEcCtD
Tapentadol—Syncope—Docetaxel—ovarian cancer	0.000714	0.00153	CcSEcCtD
Tapentadol—Pollakiuria—Epirubicin—ovarian cancer	0.000712	0.00152	CcSEcCtD
Tapentadol—Palpitations—Docetaxel—ovarian cancer	0.000703	0.0015	CcSEcCtD
Tapentadol—Loss of consciousness—Docetaxel—ovarian cancer	0.000699	0.0015	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000698	0.00149	CcSEcCtD
Tapentadol—Weight decreased—Epirubicin—ovarian cancer	0.000697	0.00149	CcSEcCtD
Tapentadol—Cough—Docetaxel—ovarian cancer	0.000694	0.00148	CcSEcCtD
Tapentadol—Insomnia—Paclitaxel—ovarian cancer	0.000693	0.00148	CcSEcCtD
Tapentadol—Convulsion—Docetaxel—ovarian cancer	0.000689	0.00147	CcSEcCtD
Tapentadol—Paraesthesia—Paclitaxel—ovarian cancer	0.000688	0.00147	CcSEcCtD
Tapentadol—Infestation NOS—Epirubicin—ovarian cancer	0.000687	0.00147	CcSEcCtD
Tapentadol—Infestation—Epirubicin—ovarian cancer	0.000687	0.00147	CcSEcCtD
Tapentadol—Dyspnoea—Paclitaxel—ovarian cancer	0.000683	0.00146	CcSEcCtD
Tapentadol—Somnolence—Paclitaxel—ovarian cancer	0.000681	0.00146	CcSEcCtD
Tapentadol—Arthralgia—Docetaxel—ovarian cancer	0.000677	0.00145	CcSEcCtD
Tapentadol—Nausea—Vinorelbine—ovarian cancer	0.000677	0.00145	CcSEcCtD
Tapentadol—Dyspepsia—Paclitaxel—ovarian cancer	0.000674	0.00144	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000673	0.00144	CcSEcCtD
Tapentadol—Urinary tract infection—Epirubicin—ovarian cancer	0.000668	0.00143	CcSEcCtD
Tapentadol—Decreased appetite—Paclitaxel—ovarian cancer	0.000666	0.00142	CcSEcCtD
Tapentadol—Dry mouth—Docetaxel—ovarian cancer	0.000663	0.00142	CcSEcCtD
Tapentadol—Upper respiratory tract infection—Doxorubicin—ovarian cancer	0.000662	0.00142	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000661	0.00141	CcSEcCtD
Tapentadol—Fatigue—Paclitaxel—ovarian cancer	0.000661	0.00141	CcSEcCtD
Tapentadol—Pollakiuria—Doxorubicin—ovarian cancer	0.000658	0.00141	CcSEcCtD
Tapentadol—Constipation—Paclitaxel—ovarian cancer	0.000655	0.0014	CcSEcCtD
Tapentadol—Confusional state—Docetaxel—ovarian cancer	0.000655	0.0014	CcSEcCtD
Tapentadol—Oedema—Docetaxel—ovarian cancer	0.000649	0.00139	CcSEcCtD
Tapentadol—Anaphylactic shock—Docetaxel—ovarian cancer	0.000649	0.00139	CcSEcCtD
Tapentadol—Infection—Docetaxel—ovarian cancer	0.000645	0.00138	CcSEcCtD
Tapentadol—Weight decreased—Doxorubicin—ovarian cancer	0.000645	0.00138	CcSEcCtD
Tapentadol—Shock—Docetaxel—ovarian cancer	0.000639	0.00137	CcSEcCtD
Tapentadol—Nervous system disorder—Docetaxel—ovarian cancer	0.000637	0.00136	CcSEcCtD
Tapentadol—Infestation NOS—Doxorubicin—ovarian cancer	0.000635	0.00136	CcSEcCtD
Tapentadol—Infestation—Doxorubicin—ovarian cancer	0.000635	0.00136	CcSEcCtD
Tapentadol—Tachycardia—Docetaxel—ovarian cancer	0.000634	0.00135	CcSEcCtD
Tapentadol—Feeling abnormal—Paclitaxel—ovarian cancer	0.000631	0.00135	CcSEcCtD
Tapentadol—Skin disorder—Docetaxel—ovarian cancer	0.000631	0.00135	CcSEcCtD
Tapentadol—Bradycardia—Epirubicin—ovarian cancer	0.000628	0.00134	CcSEcCtD
Tapentadol—Urinary tract infection—Doxorubicin—ovarian cancer	0.000618	0.00132	CcSEcCtD
Tapentadol—Hypoaesthesia—Epirubicin—ovarian cancer	0.000613	0.00131	CcSEcCtD
Tapentadol—Urinary tract disorder—Epirubicin—ovarian cancer	0.000609	0.0013	CcSEcCtD
Tapentadol—Urticaria—Paclitaxel—ovarian cancer	0.000609	0.0013	CcSEcCtD
Tapentadol—Hypotension—Docetaxel—ovarian cancer	0.000607	0.0013	CcSEcCtD
Tapentadol—Connective tissue disorder—Epirubicin—ovarian cancer	0.000606	0.0013	CcSEcCtD
Tapentadol—Urethral disorder—Epirubicin—ovarian cancer	0.000604	0.00129	CcSEcCtD
Tapentadol—Visual impairment—Epirubicin—ovarian cancer	0.000594	0.00127	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000592	0.00126	CcSEcCtD
Tapentadol—Insomnia—Docetaxel—ovarian cancer	0.000587	0.00126	CcSEcCtD
Tapentadol—Paraesthesia—Docetaxel—ovarian cancer	0.000583	0.00125	CcSEcCtD
Tapentadol—Bradycardia—Doxorubicin—ovarian cancer	0.000581	0.00124	CcSEcCtD
Tapentadol—Dyspnoea—Docetaxel—ovarian cancer	0.000579	0.00124	CcSEcCtD
Tapentadol—Somnolence—Docetaxel—ovarian cancer	0.000577	0.00123	CcSEcCtD
Tapentadol—Eye disorder—Epirubicin—ovarian cancer	0.000576	0.00123	CcSEcCtD
Tapentadol—Cardiac disorder—Epirubicin—ovarian cancer	0.000572	0.00122	CcSEcCtD
Tapentadol—Dyspepsia—Docetaxel—ovarian cancer	0.000572	0.00122	CcSEcCtD
Tapentadol—Hypoaesthesia—Doxorubicin—ovarian cancer	0.000568	0.00121	CcSEcCtD
Tapentadol—Decreased appetite—Docetaxel—ovarian cancer	0.000565	0.00121	CcSEcCtD
Tapentadol—Hypersensitivity—Paclitaxel—ovarian cancer	0.000565	0.00121	CcSEcCtD
Tapentadol—Urinary tract disorder—Doxorubicin—ovarian cancer	0.000563	0.0012	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000561	0.0012	CcSEcCtD
Tapentadol—Connective tissue disorder—Doxorubicin—ovarian cancer	0.000561	0.0012	CcSEcCtD
Tapentadol—Fatigue—Docetaxel—ovarian cancer	0.00056	0.0012	CcSEcCtD
Tapentadol—Angiopathy—Epirubicin—ovarian cancer	0.000559	0.0012	CcSEcCtD
Tapentadol—Urethral disorder—Doxorubicin—ovarian cancer	0.000559	0.0012	CcSEcCtD
Tapentadol—Immune system disorder—Epirubicin—ovarian cancer	0.000557	0.00119	CcSEcCtD
Tapentadol—Mediastinal disorder—Epirubicin—ovarian cancer	0.000556	0.00119	CcSEcCtD
Tapentadol—Constipation—Docetaxel—ovarian cancer	0.000555	0.00119	CcSEcCtD
Tapentadol—Chills—Epirubicin—ovarian cancer	0.000553	0.00118	CcSEcCtD
Tapentadol—Visual impairment—Doxorubicin—ovarian cancer	0.00055	0.00118	CcSEcCtD
Tapentadol—Asthenia—Paclitaxel—ovarian cancer	0.00055	0.00118	CcSEcCtD
Tapentadol—Pruritus—Paclitaxel—ovarian cancer	0.000542	0.00116	CcSEcCtD
Tapentadol—Mental disorder—Epirubicin—ovarian cancer	0.00054	0.00115	CcSEcCtD
Tapentadol—Malnutrition—Epirubicin—ovarian cancer	0.000537	0.00115	CcSEcCtD
Tapentadol—Feeling abnormal—Docetaxel—ovarian cancer	0.000535	0.00114	CcSEcCtD
Tapentadol—Eye disorder—Doxorubicin—ovarian cancer	0.000533	0.00114	CcSEcCtD
Tapentadol—Cardiac disorder—Doxorubicin—ovarian cancer	0.000529	0.00113	CcSEcCtD
Tapentadol—Tension—Epirubicin—ovarian cancer	0.000527	0.00113	CcSEcCtD
Tapentadol—Diarrhoea—Paclitaxel—ovarian cancer	0.000524	0.00112	CcSEcCtD
Tapentadol—Nervousness—Epirubicin—ovarian cancer	0.000521	0.00111	CcSEcCtD
Tapentadol—Angiopathy—Doxorubicin—ovarian cancer	0.000518	0.00111	CcSEcCtD
Tapentadol—Immune system disorder—Doxorubicin—ovarian cancer	0.000515	0.0011	CcSEcCtD
Tapentadol—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000514	0.0011	CcSEcCtD
Tapentadol—Chills—Doxorubicin—ovarian cancer	0.000512	0.00109	CcSEcCtD
Tapentadol—Dizziness—Paclitaxel—ovarian cancer	0.000507	0.00108	CcSEcCtD
Tapentadol—Vision blurred—Epirubicin—ovarian cancer	0.000506	0.00108	CcSEcCtD
Tapentadol—Mental disorder—Doxorubicin—ovarian cancer	0.0005	0.00107	CcSEcCtD
Tapentadol—Malnutrition—Doxorubicin—ovarian cancer	0.000497	0.00106	CcSEcCtD
Tapentadol—Agitation—Epirubicin—ovarian cancer	0.000493	0.00105	CcSEcCtD
Tapentadol—Tension—Doxorubicin—ovarian cancer	0.000487	0.00104	CcSEcCtD
Tapentadol—Vomiting—Paclitaxel—ovarian cancer	0.000487	0.00104	CcSEcCtD
Tapentadol—Rash—Paclitaxel—ovarian cancer	0.000483	0.00103	CcSEcCtD
Tapentadol—Dermatitis—Paclitaxel—ovarian cancer	0.000483	0.00103	CcSEcCtD
Tapentadol—Nervousness—Doxorubicin—ovarian cancer	0.000482	0.00103	CcSEcCtD
Tapentadol—Vertigo—Epirubicin—ovarian cancer	0.000482	0.00103	CcSEcCtD
Tapentadol—Syncope—Epirubicin—ovarian cancer	0.000481	0.00103	CcSEcCtD
Tapentadol—Headache—Paclitaxel—ovarian cancer	0.00048	0.00103	CcSEcCtD
Tapentadol—Hypersensitivity—Docetaxel—ovarian cancer	0.000478	0.00102	CcSEcCtD
Tapentadol—Palpitations—Epirubicin—ovarian cancer	0.000474	0.00101	CcSEcCtD
Tapentadol—Loss of consciousness—Epirubicin—ovarian cancer	0.000472	0.00101	CcSEcCtD
Tapentadol—Cough—Epirubicin—ovarian cancer	0.000468	0.001	CcSEcCtD
Tapentadol—Vision blurred—Doxorubicin—ovarian cancer	0.000468	0.001	CcSEcCtD
Tapentadol—Asthenia—Docetaxel—ovarian cancer	0.000466	0.000996	CcSEcCtD
Tapentadol—Convulsion—Epirubicin—ovarian cancer	0.000465	0.000994	CcSEcCtD
Tapentadol—Pruritus—Docetaxel—ovarian cancer	0.000459	0.000982	CcSEcCtD
Tapentadol—Arthralgia—Epirubicin—ovarian cancer	0.000457	0.000977	CcSEcCtD
Tapentadol—Agitation—Doxorubicin—ovarian cancer	0.000456	0.000976	CcSEcCtD
Tapentadol—Anxiety—Epirubicin—ovarian cancer	0.000455	0.000973	CcSEcCtD
Tapentadol—Nausea—Paclitaxel—ovarian cancer	0.000455	0.000973	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000454	0.00097	CcSEcCtD
Tapentadol—Dry mouth—Epirubicin—ovarian cancer	0.000447	0.000955	CcSEcCtD
Tapentadol—Vertigo—Doxorubicin—ovarian cancer	0.000446	0.000954	CcSEcCtD
Tapentadol—Syncope—Doxorubicin—ovarian cancer	0.000445	0.000952	CcSEcCtD
Tapentadol—Diarrhoea—Docetaxel—ovarian cancer	0.000444	0.00095	CcSEcCtD
Tapentadol—Confusional state—Epirubicin—ovarian cancer	0.000442	0.000944	CcSEcCtD
Tapentadol—Palpitations—Doxorubicin—ovarian cancer	0.000439	0.000938	CcSEcCtD
Tapentadol—Oedema—Epirubicin—ovarian cancer	0.000438	0.000936	CcSEcCtD
Tapentadol—Anaphylactic shock—Epirubicin—ovarian cancer	0.000438	0.000936	CcSEcCtD
Tapentadol—Loss of consciousness—Doxorubicin—ovarian cancer	0.000436	0.000933	CcSEcCtD
Tapentadol—Infection—Epirubicin—ovarian cancer	0.000435	0.00093	CcSEcCtD
Tapentadol—Cough—Doxorubicin—ovarian cancer	0.000433	0.000926	CcSEcCtD
Tapentadol—Shock—Epirubicin—ovarian cancer	0.000431	0.000921	CcSEcCtD
Tapentadol—Convulsion—Doxorubicin—ovarian cancer	0.00043	0.00092	CcSEcCtD
Tapentadol—Nervous system disorder—Epirubicin—ovarian cancer	0.00043	0.000918	CcSEcCtD
Tapentadol—Dizziness—Docetaxel—ovarian cancer	0.000429	0.000918	CcSEcCtD
Tapentadol—Tachycardia—Epirubicin—ovarian cancer	0.000428	0.000914	CcSEcCtD
Tapentadol—Skin disorder—Epirubicin—ovarian cancer	0.000425	0.00091	CcSEcCtD
Tapentadol—Hyperhidrosis—Epirubicin—ovarian cancer	0.000423	0.000905	CcSEcCtD
Tapentadol—Arthralgia—Doxorubicin—ovarian cancer	0.000423	0.000904	CcSEcCtD
Tapentadol—Anxiety—Doxorubicin—ovarian cancer	0.000421	0.000901	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.00042	0.000898	CcSEcCtD
Tapentadol—Dry mouth—Doxorubicin—ovarian cancer	0.000414	0.000884	CcSEcCtD
Tapentadol—Vomiting—Docetaxel—ovarian cancer	0.000413	0.000883	CcSEcCtD
Tapentadol—Rash—Docetaxel—ovarian cancer	0.000409	0.000875	CcSEcCtD
Tapentadol—Hypotension—Epirubicin—ovarian cancer	0.000409	0.000875	CcSEcCtD
Tapentadol—Dermatitis—Docetaxel—ovarian cancer	0.000409	0.000875	CcSEcCtD
Tapentadol—Confusional state—Doxorubicin—ovarian cancer	0.000409	0.000874	CcSEcCtD
Tapentadol—Headache—Docetaxel—ovarian cancer	0.000407	0.00087	CcSEcCtD
Tapentadol—Anaphylactic shock—Doxorubicin—ovarian cancer	0.000405	0.000866	CcSEcCtD
Tapentadol—Oedema—Doxorubicin—ovarian cancer	0.000405	0.000866	CcSEcCtD
Tapentadol—Infection—Doxorubicin—ovarian cancer	0.000403	0.000861	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000399	0.000853	CcSEcCtD
Tapentadol—Shock—Doxorubicin—ovarian cancer	0.000399	0.000852	CcSEcCtD
Tapentadol—Nervous system disorder—Doxorubicin—ovarian cancer	0.000397	0.00085	CcSEcCtD
Tapentadol—Insomnia—Epirubicin—ovarian cancer	0.000396	0.000847	CcSEcCtD
Tapentadol—Tachycardia—Doxorubicin—ovarian cancer	0.000396	0.000846	CcSEcCtD
Tapentadol—Skin disorder—Doxorubicin—ovarian cancer	0.000394	0.000842	CcSEcCtD
Tapentadol—Paraesthesia—Epirubicin—ovarian cancer	0.000393	0.000841	CcSEcCtD
Tapentadol—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000392	0.000838	CcSEcCtD
Tapentadol—Dyspnoea—Epirubicin—ovarian cancer	0.000391	0.000835	CcSEcCtD
Tapentadol—Somnolence—Epirubicin—ovarian cancer	0.000389	0.000832	CcSEcCtD
Tapentadol—Nausea—Docetaxel—ovarian cancer	0.000386	0.000825	CcSEcCtD
Tapentadol—Dyspepsia—Epirubicin—ovarian cancer	0.000386	0.000824	CcSEcCtD
Tapentadol—Decreased appetite—Epirubicin—ovarian cancer	0.000381	0.000814	CcSEcCtD
Tapentadol—Hypotension—Doxorubicin—ovarian cancer	0.000379	0.00081	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000378	0.000808	CcSEcCtD
Tapentadol—Fatigue—Epirubicin—ovarian cancer	0.000378	0.000807	CcSEcCtD
Tapentadol—Constipation—Epirubicin—ovarian cancer	0.000375	0.000801	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000369	0.000789	CcSEcCtD
Tapentadol—Insomnia—Doxorubicin—ovarian cancer	0.000367	0.000784	CcSEcCtD
Tapentadol—Paraesthesia—Doxorubicin—ovarian cancer	0.000364	0.000778	CcSEcCtD
Tapentadol—Dyspnoea—Doxorubicin—ovarian cancer	0.000361	0.000772	CcSEcCtD
Tapentadol—Feeling abnormal—Epirubicin—ovarian cancer	0.000361	0.000772	CcSEcCtD
Tapentadol—Somnolence—Doxorubicin—ovarian cancer	0.00036	0.00077	CcSEcCtD
Tapentadol—Dyspepsia—Doxorubicin—ovarian cancer	0.000357	0.000763	CcSEcCtD
Tapentadol—Decreased appetite—Doxorubicin—ovarian cancer	0.000352	0.000753	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.00035	0.000748	CcSEcCtD
Tapentadol—Fatigue—Doxorubicin—ovarian cancer	0.000349	0.000747	CcSEcCtD
Tapentadol—Urticaria—Epirubicin—ovarian cancer	0.000348	0.000744	CcSEcCtD
Tapentadol—Constipation—Doxorubicin—ovarian cancer	0.000347	0.000741	CcSEcCtD
Tapentadol—Feeling abnormal—Doxorubicin—ovarian cancer	0.000334	0.000714	CcSEcCtD
Tapentadol—Hypersensitivity—Epirubicin—ovarian cancer	0.000323	0.00069	CcSEcCtD
Tapentadol—Urticaria—Doxorubicin—ovarian cancer	0.000322	0.000688	CcSEcCtD
Tapentadol—Asthenia—Epirubicin—ovarian cancer	0.000314	0.000672	CcSEcCtD
Tapentadol—Pruritus—Epirubicin—ovarian cancer	0.00031	0.000663	CcSEcCtD
Tapentadol—Diarrhoea—Epirubicin—ovarian cancer	0.0003	0.000641	CcSEcCtD
Tapentadol—Hypersensitivity—Doxorubicin—ovarian cancer	0.000299	0.000638	CcSEcCtD
Tapentadol—Asthenia—Doxorubicin—ovarian cancer	0.000291	0.000622	CcSEcCtD
Tapentadol—Dizziness—Epirubicin—ovarian cancer	0.00029	0.000619	CcSEcCtD
Tapentadol—Pruritus—Doxorubicin—ovarian cancer	0.000287	0.000613	CcSEcCtD
Tapentadol—Vomiting—Epirubicin—ovarian cancer	0.000279	0.000595	CcSEcCtD
Tapentadol—Diarrhoea—Doxorubicin—ovarian cancer	0.000277	0.000593	CcSEcCtD
Tapentadol—Rash—Epirubicin—ovarian cancer	0.000276	0.00059	CcSEcCtD
Tapentadol—Dermatitis—Epirubicin—ovarian cancer	0.000276	0.00059	CcSEcCtD
Tapentadol—Headache—Epirubicin—ovarian cancer	0.000274	0.000587	CcSEcCtD
Tapentadol—Dizziness—Doxorubicin—ovarian cancer	0.000268	0.000573	CcSEcCtD
Tapentadol—Nausea—Epirubicin—ovarian cancer	0.00026	0.000556	CcSEcCtD
Tapentadol—Vomiting—Doxorubicin—ovarian cancer	0.000258	0.000551	CcSEcCtD
Tapentadol—Rash—Doxorubicin—ovarian cancer	0.000256	0.000546	CcSEcCtD
Tapentadol—Dermatitis—Doxorubicin—ovarian cancer	0.000255	0.000546	CcSEcCtD
Tapentadol—Headache—Doxorubicin—ovarian cancer	0.000254	0.000543	CcSEcCtD
Tapentadol—Nausea—Doxorubicin—ovarian cancer	0.000241	0.000515	CcSEcCtD
Tapentadol—UGT1A9—Metabolism—SLC2A1—ovarian cancer	2.5e-05	0.000681	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—EREG—ovarian cancer	2.46e-05	0.00067	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.45e-05	0.000667	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—ABCB1—ovarian cancer	2.43e-05	0.000662	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—IL6ST—ovarian cancer	2.42e-05	0.00066	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—CYP1B1—ovarian cancer	2.4e-05	0.000653	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—TYMS—ovarian cancer	2.38e-05	0.00065	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CYTB—ovarian cancer	2.38e-05	0.000648	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CYTB—ovarian cancer	2.36e-05	0.000643	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PPP2R1A—ovarian cancer	2.34e-05	0.000639	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—PIK3CD—ovarian cancer	2.34e-05	0.000636	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—PIK3CG—ovarian cancer	2.33e-05	0.000635	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	2.31e-05	0.000628	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PGR—ovarian cancer	2.3e-05	0.000628	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PPP1CC—ovarian cancer	2.26e-05	0.000616	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—BRIP1—ovarian cancer	2.26e-05	0.000616	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—PIK3CD—ovarian cancer	2.25e-05	0.000614	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—PIK3CB—ovarian cancer	2.24e-05	0.000611	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—PIK3CG—ovarian cancer	2.17e-05	0.000591	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—CXCL8—ovarian cancer	2.15e-05	0.000587	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PARP1—ovarian cancer	2.14e-05	0.000584	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PPP2R1A—ovarian cancer	2.12e-05	0.000579	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	2.11e-05	0.000576	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PPP1CC—ovarian cancer	2.08e-05	0.000567	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—BRIP1—ovarian cancer	2.08e-05	0.000567	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PPP1CC—ovarian cancer	2.06e-05	0.000562	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—BRIP1—ovarian cancer	2.06e-05	0.000562	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—IL2—ovarian cancer	2.06e-05	0.000561	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PPP2R1A—ovarian cancer	2.06e-05	0.00056	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—IL6ST—ovarian cancer	2.05e-05	0.000558	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—PIK3CD—ovarian cancer	2.05e-05	0.000558	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—PIK3CB—ovarian cancer	2.04e-05	0.000555	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—ABCB1—ovarian cancer	1.97e-05	0.000538	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—PIK3CG—ovarian cancer	1.97e-05	0.000536	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—PIK3CB—ovarian cancer	1.97e-05	0.000535	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—CXCL8—ovarian cancer	1.96e-05	0.000533	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—TYMS—ovarian cancer	1.94e-05	0.000528	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—CAV1—ovarian cancer	1.92e-05	0.000524	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—PIK3CD—ovarian cancer	1.91e-05	0.000519	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—CXCL8—ovarian cancer	1.89e-05	0.000515	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—IL2—ovarian cancer	1.87e-05	0.000509	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—TERT—ovarian cancer	1.86e-05	0.000507	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—IL2—ovarian cancer	1.81e-05	0.000492	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—PIK3CB—ovarian cancer	1.78e-05	0.000486	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PIK3CG—ovarian cancer	1.75e-05	0.000477	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PPP2R1A—ovarian cancer	1.74e-05	0.000473	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—PIK3CD—ovarian cancer	1.73e-05	0.000472	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CAV1—ovarian cancer	1.72e-05	0.000469	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—CXCL8—ovarian cancer	1.72e-05	0.000467	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—PIK3CB—ovarian cancer	1.66e-05	0.000453	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—ESR1—ovarian cancer	1.66e-05	0.000452	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	1.65e-05	0.000449	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—IL2—ovarian cancer	1.64e-05	0.000447	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—IL6ST—ovarian cancer	1.63e-05	0.000445	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—TERT—ovarian cancer	1.63e-05	0.000445	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—CXCL8—ovarian cancer	1.6e-05	0.000435	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PIK3CG—ovarian cancer	1.57e-05	0.000428	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—APC—ovarian cancer	1.57e-05	0.000428	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—NRAS—ovarian cancer	1.57e-05	0.000428	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—CAV1—ovarian cancer	1.56e-05	0.000425	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PIK3CD—ovarian cancer	1.54e-05	0.000419	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—IL2—ovarian cancer	1.53e-05	0.000416	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—YAP1—ovarian cancer	1.52e-05	0.000413	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CAV1—ovarian cancer	1.51e-05	0.000412	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—PIK3CB—ovarian cancer	1.51e-05	0.000411	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—MAPK3—ovarian cancer	1.5e-05	0.000409	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	1.5e-05	0.000409	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.5e-05	0.000409	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.49e-05	0.000406	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—ESR1—ovarian cancer	1.46e-05	0.000397	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—CXCL8—ovarian cancer	1.45e-05	0.000395	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—IL6ST—ovarian cancer	1.43e-05	0.00039	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—MAPK1—ovarian cancer	1.43e-05	0.00039	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—EGFR—ovarian cancer	1.43e-05	0.00039	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PIK3CG—ovarian cancer	1.42e-05	0.000388	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—YAP1—ovarian cancer	1.4e-05	0.00038	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—IL2—ovarian cancer	1.39e-05	0.000377	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—YAP1—ovarian cancer	1.38e-05	0.000377	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—TERT—ovarian cancer	1.38e-05	0.000376	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PIK3CD—ovarian cancer	1.38e-05	0.000376	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—APC—ovarian cancer	1.38e-05	0.000375	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PIK3CG—ovarian cancer	1.38e-05	0.000375	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—NRAS—ovarian cancer	1.38e-05	0.000375	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.37e-05	0.000373	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—PIK3CA—ovarian cancer	1.37e-05	0.000372	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—KRAS—ovarian cancer	1.35e-05	0.000368	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PIK3CB—ovarian cancer	1.34e-05	0.000365	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.32e-05	0.00036	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—MAPK3—ovarian cancer	1.32e-05	0.000359	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CAV1—ovarian cancer	1.28e-05	0.000348	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—MAPK1—ovarian cancer	1.25e-05	0.000342	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—EGFR—ovarian cancer	1.25e-05	0.000342	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PIK3CD—ovarian cancer	1.25e-05	0.000341	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—PIK3CA—ovarian cancer	1.24e-05	0.000338	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—FASN—ovarian cancer	1.24e-05	0.000337	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—ESR1—ovarian cancer	1.23e-05	0.000335	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—ERBB2—ovarian cancer	1.22e-05	0.000332	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—SLC5A5—ovarian cancer	1.22e-05	0.000331	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—IL6ST—ovarian cancer	1.21e-05	0.00033	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PIK3CD—ovarian cancer	1.21e-05	0.00033	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.2e-05	0.000328	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PIK3CB—ovarian cancer	1.2e-05	0.000328	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MTOR—ovarian cancer	1.2e-05	0.000328	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—PIK3CA—ovarian cancer	1.2e-05	0.000326	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—KRAS—ovarian cancer	1.18e-05	0.000323	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—SLC2A1—ovarian cancer	1.17e-05	0.00032	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—APC—ovarian cancer	1.16e-05	0.000317	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PIK3CG—ovarian cancer	1.16e-05	0.000317	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—NRAS—ovarian cancer	1.16e-05	0.000317	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PTEN—ovarian cancer	1.16e-05	0.000316	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CXCL8—ovarian cancer	1.16e-05	0.000315	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.15e-05	0.000313	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—HRAS—ovarian cancer	1.15e-05	0.000313	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—FASN—ovarian cancer	1.14e-05	0.00031	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CDKN1B—ovarian cancer	1.13e-05	0.000307	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—FASN—ovarian cancer	1.13e-05	0.000307	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CYP1B1—ovarian cancer	1.13e-05	0.000307	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—SLC5A5—ovarian cancer	1.12e-05	0.000305	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—AKT1—ovarian cancer	1.12e-05	0.000304	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—MAPK3—ovarian cancer	1.11e-05	0.000303	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—SLC5A5—ovarian cancer	1.11e-05	0.000302	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CASP3—ovarian cancer	1.11e-05	0.000301	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—IL2—ovarian cancer	1.1e-05	0.000301	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—IL6—ovarian cancer	1.1e-05	0.000299	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PIK3CB—ovarian cancer	1.09e-05	0.000297	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—PIK3CA—ovarian cancer	1.09e-05	0.000296	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—SLC2A1—ovarian cancer	1.08e-05	0.000294	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CCND1—ovarian cancer	1.08e-05	0.000293	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—SLC2A1—ovarian cancer	1.07e-05	0.000292	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—ERBB2—ovarian cancer	1.07e-05	0.000291	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CTNNB1—ovarian cancer	1.07e-05	0.00029	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—MAPK1—ovarian cancer	1.06e-05	0.000289	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—EGFR—ovarian cancer	1.06e-05	0.000289	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MTOR—ovarian cancer	1.05e-05	0.000287	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PIK3CB—ovarian cancer	1.05e-05	0.000287	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.05e-05	0.000286	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MMP9—ovarian cancer	1.05e-05	0.000285	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PTEN—ovarian cancer	1.04e-05	0.000283	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CYP1B1—ovarian cancer	1.04e-05	0.000282	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CYP1B1—ovarian cancer	1.03e-05	0.00028	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PIK3CD—ovarian cancer	1.02e-05	0.000279	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—AKT1—ovarian cancer	1.01e-05	0.000276	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CXCL8—ovarian cancer	1.01e-05	0.000276	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—PIK3CA—ovarian cancer	1.01e-05	0.000276	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—HRAS—ovarian cancer	1.01e-05	0.000274	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—KRAS—ovarian cancer	1e-05	0.000273	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PPP2R1A—ovarian cancer	9.99e-06	0.000272	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	9.94e-06	0.000271	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CDKN1B—ovarian cancer	9.9e-06	0.00027	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—AKT1—ovarian cancer	9.79e-06	0.000267	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CASP3—ovarian cancer	9.7e-06	0.000264	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—IL2—ovarian cancer	9.68e-06	0.000264	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—IL6—ovarian cancer	9.63e-06	0.000262	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CCND1—ovarian cancer	9.44e-06	0.000257	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PTEN—ovarian cancer	9.42e-06	0.000257	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—VEGFA—ovarian cancer	9.39e-06	0.000256	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CTNNB1—ovarian cancer	9.35e-06	0.000255	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—STAT3—ovarian cancer	9.29e-06	0.000253	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ABCB1—ovarian cancer	9.27e-06	0.000253	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—NRAS—ovarian cancer	9.27e-06	0.000253	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—PIK3CA—ovarian cancer	9.2e-06	0.000251	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PPP2R1A—ovarian cancer	9.19e-06	0.00025	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MMP9—ovarian cancer	9.16e-06	0.00025	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PTEN—ovarian cancer	9.11e-06	0.000248	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—TYMS—ovarian cancer	9.11e-06	0.000248	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PPP2R1A—ovarian cancer	9.11e-06	0.000248	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	9.06e-06	0.000247	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—ERBB2—ovarian cancer	9.03e-06	0.000246	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PIK3CB—ovarian cancer	8.91e-06	0.000243	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MTOR—ovarian cancer	8.91e-06	0.000243	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—AKT1—ovarian cancer	8.89e-06	0.000242	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MAPK3—ovarian cancer	8.88e-06	0.000242	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MYC—ovarian cancer	8.63e-06	0.000235	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CXCL8—ovarian cancer	8.56e-06	0.000233	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ABCB1—ovarian cancer	8.53e-06	0.000232	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—HRAS—ovarian cancer	8.51e-06	0.000232	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ABCB1—ovarian cancer	8.46e-06	0.00023	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MAPK1—ovarian cancer	8.45e-06	0.00023	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—EGFR—ovarian cancer	8.45e-06	0.00023	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—TYMS—ovarian cancer	8.38e-06	0.000228	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CDKN1B—ovarian cancer	8.36e-06	0.000228	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—TYMS—ovarian cancer	8.3e-06	0.000226	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—AKT1—ovarian cancer	8.27e-06	0.000225	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—VEGFA—ovarian cancer	8.23e-06	0.000224	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CASP3—ovarian cancer	8.2e-06	0.000223	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—IL2—ovarian cancer	8.18e-06	0.000223	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PIK3CA—ovarian cancer	8.18e-06	0.000223	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—STAT3—ovarian cancer	8.15e-06	0.000222	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—IL6—ovarian cancer	8.14e-06	0.000222	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—NRAS—ovarian cancer	8.13e-06	0.000221	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—KRAS—ovarian cancer	7.98e-06	0.000217	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CCND1—ovarian cancer	7.98e-06	0.000217	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CTNNB1—ovarian cancer	7.9e-06	0.000215	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MAPK3—ovarian cancer	7.78e-06	0.000212	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MMP9—ovarian cancer	7.75e-06	0.000211	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PTEN—ovarian cancer	7.7e-06	0.00021	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MYC—ovarian cancer	7.57e-06	0.000206	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—AKT1—ovarian cancer	7.51e-06	0.000205	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MAPK1—ovarian cancer	7.41e-06	0.000202	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—EGFR—ovarian cancer	7.41e-06	0.000202	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CAV1—ovarian cancer	7.34e-06	0.0002	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PIK3CA—ovarian cancer	7.33e-06	0.0002	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—TP53—ovarian cancer	7.09e-06	0.000193	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	7.01e-06	0.000191	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—KRAS—ovarian cancer	7e-06	0.000191	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—VEGFA—ovarian cancer	6.96e-06	0.000189	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—STAT3—ovarian cancer	6.89e-06	0.000188	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—NRAS—ovarian cancer	6.87e-06	0.000187	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—HRAS—ovarian cancer	6.78e-06	0.000185	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CAV1—ovarian cancer	6.75e-06	0.000184	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CAV1—ovarian cancer	6.69e-06	0.000182	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PIK3CG—ovarian cancer	6.68e-06	0.000182	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—AKT1—ovarian cancer	6.68e-06	0.000182	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PIK3CA—ovarian cancer	6.64e-06	0.000181	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MAPK3—ovarian cancer	6.58e-06	0.000179	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—IL6—ovarian cancer	6.49e-06	0.000177	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PIK3CA—ovarian cancer	6.43e-06	0.000175	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MYC—ovarian cancer	6.4e-06	0.000174	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	6.39e-06	0.000174	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MAPK1—ovarian cancer	6.26e-06	0.000171	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—EGFR—ovarian cancer	6.26e-06	0.000171	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—TP53—ovarian cancer	6.22e-06	0.000169	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PIK3CG—ovarian cancer	6.15e-06	0.000168	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PIK3CG—ovarian cancer	6.1e-06	0.000166	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—AKT1—ovarian cancer	5.99e-06	0.000163	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—HRAS—ovarian cancer	5.95e-06	0.000162	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—KRAS—ovarian cancer	5.91e-06	0.000161	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PIK3CD—ovarian cancer	5.88e-06	0.00016	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—IL6—ovarian cancer	5.69e-06	0.000155	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PIK3CA—ovarian cancer	5.43e-06	0.000148	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—AKT1—ovarian cancer	5.43e-06	0.000148	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PIK3CD—ovarian cancer	5.41e-06	0.000147	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PIK3CD—ovarian cancer	5.36e-06	0.000146	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—TP53—ovarian cancer	5.26e-06	0.000143	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—AKT1—ovarian cancer	5.25e-06	0.000143	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PIK3CB—ovarian cancer	5.12e-06	0.00014	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—HRAS—ovarian cancer	5.03e-06	0.000137	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—IL6—ovarian cancer	4.81e-06	0.000131	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PIK3CB—ovarian cancer	4.71e-06	0.000128	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PIK3CB—ovarian cancer	4.67e-06	0.000127	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—AKT1—ovarian cancer	4.44e-06	0.000121	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PTEN—ovarian cancer	4.43e-06	0.000121	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PTEN—ovarian cancer	4.07e-06	0.000111	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PTEN—ovarian cancer	4.04e-06	0.00011	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PIK3CA—ovarian cancer	3.12e-06	8.51e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PIK3CA—ovarian cancer	2.87e-06	7.82e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PIK3CA—ovarian cancer	2.85e-06	7.76e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—AKT1—ovarian cancer	2.55e-06	6.95e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—AKT1—ovarian cancer	2.35e-06	6.39e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—AKT1—ovarian cancer	2.33e-06	6.34e-05	CbGpPWpGaD
